Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are starting the week higher!
Seems to be some mini-whaling going on here this week as the $BIXT share price rises.
I feel a disturbance in the force..
Yes, Plus the possible research on Monkey pox.
Now with OTCQB Certification filed, I’m wondering how long that will take to grant?
Greater than 280,000 shares traded yesterday! Maybe that was on the potential of the OtcQB status about to happen ?
Otc market.com
8/8/22 OTCQB Certification
Filing
< 111.5M shares
This is great news!
Those warrants would have diluted the OS of the company if exercised!
Now they are canceled!
BIXT could have a huge run here!
SEC nailed some bad con debt folks in NY, news came out a day ago, and the bad folks must return all the shares, cancel all the debt, cancel all the warrants of all the OTC stocks they were milking.
They had BIXT warrants, which if they were under the current retail are now not only dead, but no longer holding us back. Official company news could be leased by all the companies, including BIXT.
https://www.sec.gov/news/press-release/2022-135
5/2
5/9
6/6
5/13
5/20
577
nhibit..
pister
BIXT
Ex
CSTI
GTSM
INTL
PUMA
NITE
TEEN
BIOXYTRAN INC COM
Bid
43000
42000
40200
40200
40000
BS
3.000
140.000( look at this)
2,500
À500
3.000
TAnn
718
7/25
T
"' QQT Drawing set: Default
- O0405
43435
Level Il
E3
OTOX
GTEM
INTL
CSTI
NITE
Ask
43990
44000
47900
50000
50000
AS
2,500
2.500
2.500
2.500
2.500
ann
GALT gets $60M!
If BIXT would get $60 million We will be $1 billion company in a year!
PS: look at history of GALT
Looking at company website Dr. Platt has had a number of successful companies and Innovative new drugs!
$BIXT heading back up today. Just needs eyes. Any volume and this beast rockets to $ land in 1-2 days. Will not take much volume either..
easier to get in India for sure
Found what I was missing. There was a trial, in India. Next step FDA?
https://www.walshmedicalmedia.com/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html
"About ProLectin-M:
ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus. ProLectin-M is expected to interfere with the binding of the virus to the cell and thereby prevent viral entry into cells.
Preclinical in-vitro and in-vivo preliminary data shows that ProLectin-M is non-toxic for humans. ProLectin-M was used in an open label, randomized, controlled clinical feasibility study in COVID-19 patients with mild-to-moderate COVID-19 disease".
Does this mean they are already going to file for an FDA EUA authorization?
Or still need further trials in a phase III?
That is the first I had seen the claim of the feasibility study...already being done. That is huge, but what is next?
Pretty awesome news folks. We are waiting to find out FDA time lines, but my gut (and understanding of the bio-chemistry) says this could be the next Moderna blow out in 1-2 years. All depends on the trial timelines, and Covid19 variants. But BA 5 Covid19 is already as contagious as the measles and CDC/FDA and folks on the hot seat will be funding all sorts of opportunities and helping to get new solutions rushed to market (Limited delays, using the EUA trial process, that cuts 5-10 years off of trials...)
I called the rally on Moderna in March 2020. And Moderna rallied 10X higher than even I expected. And Moderna had hundred of millions of looses, trading on the big boards...
Omicron has out maneuvered the vaccines and adapted over time. And Antivirals like Pfizer's Paxlovid are getting their turn, but if BIXT's stuff works in 3 days with out a rebound, that will be huge.
We still need and FDA EUA trial, and they take time. But even now, IMO, this looks undervalued, 100 to 200% undervalued already even at this stage.
https://sciencescholar.us/journal/index.php/ijhs/article/view/10033
https://www.nejm.org/doi/full/10.1056/NEJMc2206576
Six months after the initial two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 against WA1/2020 but less than 20 against all the tested omicron subvariants (Figure 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer increased substantially, to 5783 against the WA1/2020 isolate, 900 against the BA.1 subvariant, 829 against the BA.2 subvariant, 410 against the BA.2.12.1 subvariant, and 275 against the BA.4 or BA.5 subvariant.
These data show that as compared with the response against the WA1/2020 isolate, the neutralizing antibody titer was lower by a factor of 6.4 against BA.1, by a factor of 7.0 against BA.2, by a factor of 14.1 against BA.2.12.1, and by a factor of 21.0 against BA.4 or BA.5.
In addition, as compared with the median neutralizing antibody titer against the BA.1 subvariant, the median titer was lower by a factor of 2.2 against the BA.2.12.1 subvariant and by a factor of 3.3 against the BA.4 or BA.5 subvariant.
Conclusion, Omicron BA 4 and 5 are winning. and are just as contageous as the measles
*
Among the participants with a history of Covid-19, the median neutralizing antibody titer was 11,050 against the WA1/2020 isolate, 1740 against the BA.1 subvariant, 1910 against the BA.2 subvariant, 1150 against the BA.2.12.1 subvariant, and 590 against the BA.4 or BA.5 subvariant
(even natural immunity from prior infections is not high enough for BA 5)
*
These data show that the BA.2.12.1, BA.4, and BA.5 subvariants substantially escape neutralizing antibodies induced by both vaccination and infection. Moreover, neutralizing antibody titers against the BA.4 or BA.5 subvariant and (to a lesser extent) against the BA.2.12.1 subvariant were lower than titers against the BA.1 and BA.2 subvariants, which suggests that the SARS-CoV-2 omicron variant has continued to evolve with increasing neutralization escape. These findings provide immunologic context for the current surges caused by the BA.2.12.1, BA.4, and BA.5 subvariants in populations with high frequencies of vaccination and BA.1 or BA.2 infection.
Pretty awesome news folks. We are waiting to find out FDA time lines, but my gut (and understanding of the bio-chemistry) says this could be the next Moderna blow out in 1-2 years. All depends on the trial timelines, and Covid19 variants. But BA 5 Covid19 is already as contagious as the measles and CDC/FDA and folks on the hot seat will be funding all sorts of opportunities and helping to get new solutions rushed to market (Limited delays, using the EUA trial process, that cuts 5-10 years off of trials...)
I called the rally on Moderna in March 2020.
https://sciencescholar.us/journal/index.php/ijhs/article/view/10033
https://www.nejm.org/doi/full/10.1056/NEJMc2206576
Six months after the initial two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 against WA1/2020 but less than 20 against all the tested omicron subvariants (Figure 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer increased substantially, to 5783 against the WA1/2020 isolate, 900 against the BA.1 subvariant, 829 against the BA.2 subvariant, 410 against the BA.2.12.1 subvariant, and 275 against the BA.4 or BA.5 subvariant.
These data show that as compared with the response against the WA1/2020 isolate, the neutralizing antibody titer was lower by a factor of 6.4 against BA.1, by a factor of 7.0 against BA.2, by a factor of 14.1 against BA.2.12.1, and by a factor of 21.0 against BA.4 or BA.5. In addition, as compared with the median neutralizing antibody titer against the BA.1 subvariant, the median titer was lower by a factor of 2.2 against the BA.2.12.1 subvariant and by a factor of 3.3 against the BA.4 or BA.5 subvariant.
Conclusion, Omicron BA 4 and 5 are winning. and are just as contageous as the measles
*
Among the participants with a history of Covid-19, the median neutralizing antibody titer was 11,050 against the WA1/2020 isolate, 1740 against the BA.1 subvariant, 1910 against the BA.2 subvariant, 1150 against the BA.2.12.1 subvariant, and 590 against the BA.4 or BA.5 subvariant
*
These data show that the BA.2.12.1, BA.4, and BA.5 subvariants substantially escape neutralizing antibodies induced by both vaccination and infection. Moreover, neutralizing antibody titers against the BA.4 or BA.5 subvariant and (to a lesser extent) against the BA.2.12.1 subvariant were lower than titers against the BA.1 and BA.2 subvariants, which suggests that the SARS-CoV-2 omicron variant has continued to evolve with increasing neutralization escape. These findings provide immunologic context for the current surges caused by the BA.2.12.1, BA.4, and BA.5 subvariants in populations with high frequencies of vaccination and BA.1 or BA.2 infection.
big news Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
https://www.otcmarkets.com/stock/BIXT/news/story?e&id=2279828
ProLectin-M, a new class of oral antiviral drug
BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below. ProLectin-M is the Company’s leading drug molecule in its pipeline to treat viral infections.
The journal article begins to outline and further define the mechanism of action (MOA) behind the oral galectin inhibitor Prolectin-M. The article confirms and further expands on the preliminary clinical data results from Bioxytran’s first peer-reviewed journal article in the Journal of Vaccines & Vaccination2, “Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial”, whereby human clinical trial results showed elimination of viral load to undetectable levels within a few days. The analytical tests within the scope of this most recent journal article utilize some of the most rigorously binding tests between a Lectin class of protein and carbohydrates.
1) https://sciencescholar.us/journal/index.php/ijhs/article/view/10033
2) https://www.walshmedicalmedia.com/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases and bind to the conserved region of the spike protein commonly known as the galectin fold. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
About Galectins
Galectins are carbohydrate-binding proteins that are involved in many physiological functions, such as inflammation, immune responses, cell migration, autophagy, and signaling. They are also linked to diseases such as fibrosis, cancer and heart disease.
About Lectins
Galectins are a class of specific lectins. Lectins are a special class of proteins widely distributed in nature, which selectively recognize and reversibly bind to carbohydrates and glycoconjugates through their binding sites. These proteins, which can be detected through hemagglutination assays, interact with different carbohydrates present in cell and viral surfaces.
About ProLectin-M
ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus. ProLectin-M is expected to interfere with the binding of the virus to the cell and thereby prevent viral entry into cells. Preclinical in-vitro and in-vivo preliminary data shows that ProLectin-M is non-toxic for humans. ProLectin-M was used in an open label, randomized, controlled clinical feasibility study in COVID-19 patients with mild-to-moderate COVID-19 disease.
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
New science Glycovirology!
https://t.co/65l7jNM322
That is great news :
Big news:
You can now place an order on line in Schwab online or streetsmartedge platform!
Since we started trading on 6/14 you had to call them on the phone to place an order.
On 6/16 stock hit .58!
Big news:
You can now place an order on line in Schwab online or streetsmartedge platform!
Since we started trading on 6/14 you had to call them on the phone to place an order.
On 6/16 stock hit .58!
Yes! I think that is happening!
Mike check out va*pr…thoughts?
I can always tell when a great stock is being stealth accumulated.
The silence is deafening, and the fish nibble up shares hoping not to awake up the whales....
$BIXT
Yes. It’s going to be epic
As one by one major viruses start to be taken down world wide!
The Ninja Covid19 variant cometh? and $BIXT is plotting its funeral?
I love it, the Next Hollywood clot shot- Andromeda Strain block buster movie
Look at BIXT : www.bioxytraninc.com
Glycovirology is a totally newly science emerging from this company.
Here comes the scary, end of the world as we know it, get boosted 300 times, trust the science, wear N95 or full hasmat suit NINJA ??variant
Up 100% already just this month from the back test low. Testing 50 cents now $BIXT
Huge volume day today with some high percentage gain in stock price!
This is a new Molecule
https://www.mdpi.com/1422-0067/23/14/7739
One sign of great stock is when it rallies as the market crashes. $BIXT getting some love at the ask today
I should have bought more on that dip...
I was told that most of the selling in BIXT over the past few weeks has been from one investor dumping shares. Their position is probably clearing out this week and we should start to see upward movement.
$BIXT is one of the few stocks that is green this morning. All the rest seem to fighting some kind of bug, LOL, bleeding red
I agree ! In my opinion Anything under .50 is a good buy! I think we are going higher !
Shareholders don’t know it’s trading
No press releases!
No 8K stated trademark name ProLectin and 2 patents!
Nets out on the bid time today in BIXT-ville.
This is the time to buy in volume IMO
Interesting find on Galectin...
$BIXT nice bounce today
https://www.walshmedicalmedia.com/abstract/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html
BIXT up 16.9% this stock moves on air... Thin ask above
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |